Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771671

Citations 4

Authors

Vincent Fregona

Manon Bayet

Bastien Gerby

Affiliations

Soon will be listed here.

Abstract

Our understanding of the hierarchical structure of acute leukemia has yet to be fully translated into therapeutic approaches. Indeed, chemotherapy still has to take into account the possibility that leukemia-initiating cells may have a distinct chemosensitivity profile compared to the bulk of the tumor, and therefore are spared by the current treatment, causing the relapse of the disease. Therefore, the identification of the cell-of-origin of leukemia remains a longstanding question and an exciting challenge in cancer research of the last few decades. With a particular focus on acute lymphoblastic leukemia, we present in this review the previous and current concepts exploring the phenotypic, genetic and functional heterogeneity in patients. We also discuss the benefits of using engineered mouse models to explore the early steps of leukemia development and to identify the biological mechanisms driving the emergence of leukemia-initiating cells. Finally, we describe the major prospects for the discovery of new therapeutic strategies that specifically target their aberrant stem cell-like functions.

Citing Articles

In Vitro Purging of Acute Lymphoblastic Leukemia (B-ALL) Cells with the Use of PTL, DMAPT, or PU-H71.

Ortiz-Reyes A, Garcia-Sanchez S, Serrano M, Nunez-Enriquez J, Alvarado-Moreno J, Montesinos J Int J Mol Sci. 2024; 25(21).

PMID: 39519261 PMC: 11546800. DOI: 10.3390/ijms252111707.

Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.

Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog L J Exp Med. 2023; 221(1).

PMID: 37930337 PMC: 10626194. DOI: 10.1084/jem.20230279.

Lessons from mouse models in the impact of risk factors on the genesis of childhood B-cell leukemia.

Casado-Garcia A, Isidro-Hernandez M, Aleman-Arteaga S, Ruiz-Corzo B, Riesco S, Prieto-Matos P Front Immunol. 2023; 14:1285743.

PMID: 37901253 PMC: 10602728. DOI: 10.3389/fimmu.2023.1285743.

Monoallelic Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.

Veiga D, Tremblay M, Gerby B, Herblot S, Haman A, Gendron P Front Immunol. 2022; 13:867443.

PMID: 35401501 PMC: 8987207. DOI: 10.3389/fimmu.2022.867443.

References

Inaba H, Mullighan C . Pediatric acute lymphoblastic leukemia. Haematologica. 2020; 105(11):2524-2539. PMC: 7604619. DOI: 10.3324/haematol.2020.247031. View

Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer M . Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med. 2012; 5(1):38-51. PMC: 3569652. DOI: 10.1002/emmm.201201703. View

Shah S, Schrader K, Waanders E, Timms A, Vijai J, Miething C . A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013; 45(10):1226-1231. PMC: 3919799. DOI: 10.1038/ng.2754. View

Nera K, Kohonen P, Narvi E, Peippo A, Mustonen L, Terho P . Loss of Pax5 promotes plasma cell differentiation. Immunity. 2006; 24(3):283-93. DOI: 10.1016/j.immuni.2006.02.003. View

Spangrude G, Heimfeld S, Weissman I . Purification and characterization of mouse hematopoietic stem cells. Science. 1988; 241(4861):58-62. DOI: 10.1126/science.2898810. View

Abdulla H, Vo A, Shields B, Davies T, Jackson J, Alserihi R . T-ALL can evolve to oncogene independence. Leukemia. 2021; 35(8):2205-2219. DOI: 10.1038/s41375-021-01120-9. View

Vicente-Duenas C, Janssen S, Oldenburg M, Auer F, Gonzalez-Herrero I, Casado-Garcia A . An intact gut microbiome protects genetically predisposed mice against leukemia. Blood. 2020; 136(18):2003-2017. PMC: 7694022. DOI: 10.1182/blood.2019004381. View

Theunissen P, de Bie M, van Zessen D, de Haas V, Stubbs A, van der Velden V . Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection. Leuk Res. 2018; 76:98-104. DOI: 10.1016/j.leukres.2018.10.009. View

Peaudecerf L, Krenn G, Goncalves P, Vasseur F, Rocha B . Thymocytes self-renewal: a major hope or a major threat?. Immunol Rev. 2016; 271(1):173-84. DOI: 10.1111/imr.12408. View

10.

Richter-Pechanska P, Kunz J, Bornhauser B, von Knebel Doeberitz C, Rausch T, Erarslan-Uysal B . PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. EMBO Mol Med. 2018; 10(12). PMC: 6284381. DOI: 10.15252/emmm.201809443. View

11.

Taussig D, Miraki-Moud F, Anjos-Afonso F, Pearce D, Allen K, Ridler C . Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008; 112(3):568-75. DOI: 10.1182/blood-2007-10-118331. View

12.

Bijl J, Sauvageau M, Thompson A, Sauvageau G . High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia. Genes Dev. 2005; 19(2):224-33. PMC: 545883. DOI: 10.1101/gad.1268505. View

13.

Huntly B, Shigematsu H, Deguchi K, Lee B, Mizuno S, Duclos N . MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015. View

14.

Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D . Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021; 12(1):865. PMC: 7870924. DOI: 10.1038/s41467-021-21168-6. View

15.

Lacombe J, Herblot S, Rojas-Sutterlin S, Haman A, Barakat S, Iscove N . Scl regulates the quiescence and the long-term competence of hematopoietic stem cells. Blood. 2009; 115(4):792-803. DOI: 10.1182/blood-2009-01-201384. View

16.

le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A . In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008; 14(1):47-58. PMC: 2572185. DOI: 10.1016/j.ccr.2008.05.015. View

17.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

18.

Duque-Afonso J, Feng J, Scherer F, Lin C, Wong S, Wang Z . Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia. J Clin Invest. 2015; 125(9):3667-80. PMC: 4588292. DOI: 10.1172/JCI81158. View

19.

Verdine G, Walensky L . The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007; 13(24):7264-70. DOI: 10.1158/1078-0432.CCR-07-2184. View

20.

Familiades J, Bousquet M, Lafage-Pochitaloff M, Bene M, Beldjord K, De Vos J . PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009; 23(11):1989-98. DOI: 10.1038/leu.2009.135. View